Search

Your search keyword '"Sho Sato"' showing total 8 results
Start Over Author "Sho Sato" Journal internal medicine
8 results on '"Sho Sato"'

4. Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C

Author

Ayato Murata, Yuji Kita, Sho Sato, Daishi Kabemura, Hironori Tsuzura, Noboru Yatagai, Takuya Genda, Shunsuke Sato, Yuji Shimada, Nozomi Amano, and Yuji Ikeda

Subjects
hepatitis C virus, HBsAg, Hepatitis B virus, Sofosbuvir, ribavirin, Hepatitis C virus, Case Report, Hepacivirus, 030204 cardiovascular system & hematology, medicine.disease_cause, Hepatitis b surface antigen, sofosbuvir, Antiviral Agents, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal Medicine, medicine, Humans, Retrospective Studies, Hepatitis B Surface Antigens, business.industry, Ribavirin, virus diseases, General Medicine, Hepatitis C, Hepatitis B, Hepatitis C, Chronic, medicine.disease, Virology, digestive system diseases, hepatitis B surface antigen, chemistry, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

Direct-acting antiviral (DAA) therapy carries a potential risk of inducing hepatitis B virus (HBV) reactivation. However, the HBV kinetics during and after DAA therapy in patients co-infected with hepatitis C virus (HCV) and HBV remain unknown. We retrospectively evaluated the HBV kinetics during and after sofosbuvir/ribavirin therapy in four HBV inactive carriers co-infected with HCV. HCV was eradicated in all patients. Changes in HBV-DNA levels during treatment differed among patients. The hepatitis B surface antigen (HBsAg) levels uniformly decreased (mean -0.530 logIU/mL) by the end of treatment and returned to near the baseline in all patients. Sofosbuvir/ribavirin therapy thus demonstrated a suppressive effect on HBsAg.

Published
2021

5. Mucinous Cystadenocarcinoma of the Pancreas with Cyst Infection in a Male Patient

Author

Kouhei Matsumoto, Mako Ushio, Hironori Tsuzura, Hiroyuki Isayama, Nozomi Amano, Shunsuke Sato, Yuki Fukumura, Sho Sato, Toshio Fujisawa, Ko Tomishima, Yuji Shimada, Takuya Genda, and Ayato Murata

Subjects
Male, Pathology, medicine.medical_specialty, CA-19-9 Antigen, pancreatic cancer, Case Report, 030204 cardiovascular system & hematology, Cystadenocarcinoma, Mucinous, 03 medical and health sciences, Pancreatectomy, 0302 clinical medicine, Pancreatic cancer, Internal Medicine, medicine, Humans, Cyst, Pancreas, MCC, Type 1 diabetes, Intraductal papillary mucinous neoplasm, business.industry, cyst in cyst, General Medicine, MCN, Middle Aged, medicine.disease, Cystic Neoplasm, Pancreatic Neoplasms, medicine.anatomical_structure, Male patient, 030211 gastroenterology & hepatology, Pancreatic Cyst, Mucinous cystadenocarcinoma, Tomography, X-Ray Computed, business
Abstract

Follow-up computed tomography revealed a 40-mm pancreatic tail cyst in a 59-year-old man with type 1 diabetes mellitus. An intraductal papillary mucinous neoplasm was suspected; mucinous cystic neoplasm (MCN) was not considered because the patient was a man. During follow-up, cyst infection occurred but was improved by conservative treatment. At the 24-month follow up examination, cyst nodules had developed, corresponding to an increase in the carbohydrate antigen 19-9 level. Mucinous cystadenocarcinoma (MCC) was diagnosed pathologically based on distal pancreatectomy. A diagnosis of male MCN/MCC is often delayed, which may lead to a poor prognosis. MCN infection is also rare and poorly recognized. We observed an atypical male case of MCN/MCC.

Published
2020

6. Eosinophilic Gastroenteritis in an Ulcerative Colitis Patient During Treatment with Tumor Necrosis Factor-alpha Antagonist

Author

Sho Takahashi, Yuji Shimada, Hironori Tsuzura, Sho Sato, Akihito Nagahara, Takuya Genda, Shunsuke Sato, Nozomi Amano, Sho Hayashida, Ayato Murata, and Yuji Ikeda

Subjects
Male, eosinophilic gastroenteritis, Abdominal pain, medicine.medical_specialty, tumor necrosis factor-alpha antagonist, Prednisolone, Case Report, 030204 cardiovascular system & hematology, Gastroenterology, ascites, 03 medical and health sciences, Esophagus, 0302 clinical medicine, Ileum, Internal medicine, Eosinophilia, Ascites, Internal Medicine, medicine, Eosinophilic gastroenteritis, Humans, Endoscopy, Digestive System, Glucocorticoids, ulcerative colitis, business.industry, Stomach, Rectum, Antibodies, Monoclonal, Colonoscopy, General Medicine, Middle Aged, Eosinophil, medicine.disease, Ulcerative colitis, Enteritis, Golimumab, Eosinophils, medicine.anatomical_structure, Gastritis, Colitis, Ulcerative, Tumor Necrosis Factor Inhibitors, 030211 gastroenterology & hepatology, medicine.symptom, Tomography, X-Ray Computed, business, medicine.drug
Abstract

A 45-year-old man with steroid-dependent ulcerative pancolitis was hospitalized with frequent diarrhea, abdominal pain and distension 3 months after induction of golimumab, a tumor necrosis factor-alpha antagonist. Computed tomography showed wall thickening from the stomach to the colon and massive ascites. Peripheral blood test revealed eosinophilia. A large number of eosinophils were observed in the ascites fluid. Although esophagogastroduodenoscopy showed no abnormal findings and colonoscopy showed ulcerative colitis with a Mayo endoscopic subscore of 1, eosinophil infiltration was histologically observed. Based on these findings, we diagnosed him with eosinophilic gastroenteritis and started prednisolone. Consequently, his eosinophil counts and abdominal symptoms dramatically improved.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results